| 摘要 |
One or more of the cannabinoids cannabichromene (CBC), cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA) for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably, the neurodegenerative disease is selected from Alzheimerâ s disease, Parkinsonâ s disease, amyotrophic lateral sclerosis and Huntingtonâ s disease, in particular, Alzheimerâ s disease. Alternatively, the neurodegenerative disorder may be selected from stroke, cardiac ischemia, coronary artery disease, thromboembolism, myocardial infarction or an ischemia related disease. Preferably the cannabinoid is present in an amount of between 5mg to 1000mg and may be used in combination with one or more other medicinal substances. The cannabinoids may also be present in the form of a botanical drug substance (BDS). |
